Immix Biopharma, Inc. 4

Director Jane Buchan received 6,250 RSUs and an option for 12,500 shares of Immix Biopharma, Inc. common stock as equity awards on May 22, 2026.

On May 22, 2026, reporting person Jane Buchan received an equity compensation package from Immix Biopharma, Inc. consisting of 6,250 restricted stock units and a stock option for 12,500 shares of common stock at an exercise price of $8.78 per share under the company’s 2021 Equity Incentive Plan. The RSUs will vest in full on the earlier of the one-year anniversary of the grant date or the date of Immix’s 2027 annual stockholders’ meeting, while the stock option will vest in substantially equal monthly installments over 12 months following the grant date (or fully at the 2027 annual meeting if that occurs earlier), in each case subject to her continued service with the company. Following these awards, Buchan beneficially owned 28,705 shares of common stock directly, and held options for an additional 12,500 shares, representing routine director-level equity compensation rather than open-market purchases or sales.

Filing Facts

CIK

1873835

Ticker

IMMX

Form

4

Source Type

sec

Accession

0001493152-26-026423

Alert Tier

5